The present invention provides a method for evaluating intracellular or extracellular enzyme activity of CYP enzyme group, including a step of measuring the number of molecules of oxidized CYP enzyme group.

Compositions and methods for individualized therapy of pain using a non-steroidal anti-inflammatory drug (NSAID) and an anti-hypertensive without inducing intolerable edema. Said methods comprise basing NSAID/anti-hypertensive dose on each patient's pharmacokinetic response to said NSAID.

The present disclosure relates to methods of using biomarkers as early disease and patient outcome predictors. More particularly, the present disclosure encompasses methods of predicting cancer metastasis by detecting and/or quantifying aspartyl (asparaginyl) beta hydroxylase (HAAH) and matrix metalloproteinase 9 (MMP9) in a biological sample.

A method and kit for predicting preeclampsia is provided. Levels of Jumonji C domain containing protein 6 (JMJD6) and fibronectin are measured in placenta-derived small extracellular vesicles isolated from a subject. The levels of JMJD6 and fibronectin are compared to a non-preeclamptic control. If levels of JMJD6 are depressed and levels of fibronectin are elevated, the subject may be monitored or treated for preeclampsia.

Provided herein are analytical methods utilizing a self-limiting catalytic reaction, and compositions and kits useful therefore. In one aspect the method is used to quantify Pd, and in another, the method is a horseradish peroxidase assay.

An automated method of evaluating a collected fluid sample includes: filling a sample cavity with the collected fluid sample; adding a buffer solution; separating the collected fluid sample into a first portion and a second portion; mixing the second portion with tagged antibodies; removing leftover tagged antibodies; and measuring a difference between the first portion and the second portion. A sample collection and testing device includes: a reference cavity comprising a reference fluid sample; a test cavity comprising a test fluid sample; a reference measurement element associated with the reference cavity; and a test measurement element associated with the test cavity. A method of evaluating a collected fluid sample including: separating the sample; pumping a first portion to a first measurement cavity; adding a solution to a second portion and pumping the mixture to a second measurement cavity; and measuring a charge difference between the first and second measurement cavities.

Compositions and methods useful for treating a number of human disorders including, but not limited to, cancer, cardiovascular disease, obesity, and metabolic disorders are provided. For example, the disclosure features compositions and methods for modulating the hydroxylation of ACC2 by PHD3 in vitro or in vivo. Also provided are methods for monitoring and/or detecting the expression of PHD3 and/or levels of ACC2 hydroxylation, which are useful for, inter alia, determining whether a cancer cell is sensitive to glycolytic pathway inhibitors or inhibitors of fatty acid metabolism.

A fluorescent probe for measurement of CYP3A activity, having an excellent CYP molecular species selectivity and detection sensitivity represented is represented by the following formula:

##STR00001##

In the formula, R.sup.1 represents a monovalent group, R.sup.2 represents a hydrogen atom or a monovalent group, R.sup.3 and R.sup.4 each independently represent a hydrogen atom, a halogen atom, an alkyl group or an alkoxy group, R.sup.5 represents a monovalent group selected so that the ether bond of the O-benzyl moiety at the 6th position of the compound represented by formula (I) is oxidatively cleavable by the molecular species 3A of the cytochrome P-450, n represents an integer from 1 to 5, and when n is 2 or more, all or a part of the plurality of R.sup.5s may be the same as each other or different from each other.

A novel class of hydroxylases is described having the amino acid sequence of SEQ ID NO: 2, 4, 6 and 8, and variants and fragments thereof having HIF hydroxylation activity. The polypeptides of the invention have in particular prolyl hydroxylase activity. An assay method monitors the interaction of the HIF hydroxylase with a substrate. Modulators of HIF hydroxylase are provided for use in the treatment of a condition associated with increased or decreased HIF levels or activity or for the treatment of a condition where it is desirable to modulate HIF levels or activity.

A novel class of hydroxylases is described having the amino acid sequence of SEQ ID NO: 2, 4, 6 and 8, and variants and fragments thereof having HIF hydroxylation activity. The polypeptides of the invention have in particular prolyl hydroxylase activity. An assay method monitors the interaction of the HIF hydroxylase with a substrate. Modulators of HIF hydroxylase are provided for use in the treatment of a condition associated with increased or decreased HIF levels or activity or for the treatment of a condition where it is desirable to modulate HIF levels or activity.